BioWorld

Feb. 10, 2006

Elan Sells European Prialt Rights To Eisai For $100M

Elan Corp. plc decided to sell the European rights to its pain product Prialt, but is keeping U.S. rights, where the drug already is being sold. (BioWorld Today) Read More

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Diversified Risk Important To Investors In Stem Cells

Series A Now Done, Proacta Has Funds To Fight Tumors

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...